The current financial score of Solid Biosciences Inc is 6.75. Its financial status is robust, and its operating efficiency is low.
The current valuation score of Solid Biosciences Inc is 6.64. Its current P/E ratio is -4.18, which is -101.26% below the recent high of 0.05 and -39.03% above the recent low of -5.82.
The current earnings forecast score of Solid Biosciences Inc is 8.92. The average price target is 18.92, with a high of 26.00 and a low of 14.00.
The current price momentum score of Solid Biosciences Inc is 4.19. Currently, the stock price is trading between the resistance level at 9.66 and the support level at 7.19, making it suitable for range-bound swing trading.
The current institutional shareholding score of Solid Biosciences Inc is 7.00. The latest institutional shareholding proportion is 85.25%, representing a quarter-over-quarter decrease of 19.69%. The largest institutional shareholder is James Simons, holding a total of 82.10K shares, representing 0.00% of shares outstanding, with 14.97% increase in holdings.
The current risk assessment score of Solid Biosciences Inc is 5.45. The company's beta value is 2.43. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.